

Reviews in Cardiovascular Medicine Subject Index to Volume 2

ACE inhibitors

Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.

Acute coronary events

Vogel RA. C-reactive protein as a predictor of coronary event risk [Literature Review]. 2(4):224–225.

Acute coronary syndrome

Best of the AHA Scientific Sessions 2000 [Meeting Review]. 2(1):6–24, 60.

Leopold JA, Jacobs AK. Catheter-based revascularization strategies for acute coronary syndromes in women. 2(4):181–189.

Acute myocardial infarction

Leopold JA, Jacobs AK. Catheter-based revascularization strategies for acute coronary syndromes in women. 2(4):181–189.

Acute renal failure

Mathur VS. Pathophysiology of radiocontrast nephropathy and use of fenoldopam for its prevention. 2(suppl 1):S4–S8.

Mehran R, Ashby DT. Radiocontrast-induced acute renal failure: allocations and outcomes. 2(suppl 1):S9–S13.

Acute tubular necrosis

Mathur VS. Pathophysiology of radiocontrast nephropathy and use of fenoldopam for its prevention. 2(suppl 1):S4–S8.

Adverse drug event

Martin Stone S, Neepa R, Nei J. Problems and pitfalls in cardiac drug therapy. 2(3):126–142.

Adverse drug reaction

Martin Stone S, Neepa R, Nei J. Problems and pitfalls in cardiac drug

therapy. 2(3):126–142.

Aneurysm

Creager MA. Current issues in vascular disease [Meeting Review]. 2(2):92–93.

Aneurysm, dissecting

Kar S, Shah PK. Acute coronary syndrome caused by coronary artery dissection mimicking acute plaque rupture. 2(4):215–219.

Angina pectoris

Dillon GA, Jacobs AK. Acute coronary syndrome in a young woman. 2(3):166:171.

Angiogenesis

Yeung AC. The role of nitric oxide in atherogenesis [Literature Review]. 2(2):108.

Angiography

Mathur VS. Pathophysiology of radiocontrast nephropathy and use of fenoldopam for its prevention. 2(suppl 1):S4–S8.

Angioplasty

Kar S, Shah PK. Acute coronary syndrome caused by coronary artery dissection mimicking acute plaque rupture. 2(4):215–219.

Leopold JA, Jacobs AK. Catheter-based revascularization strategies for acute coronary syndromes in women. 2(4):181–189.

Angiotensin-converting enzyme inhibitor

Lepor NE. Best of the 2001 ACC annual Snowmass Cardiovascular Conference [Meeting Review]. 2(4):206–208.

Anorexigens

Best of the AHA Scientific Sessions

2000 [Meeting Review]. 2(1):6–24, 60.

Antiarrhythmic drugs

Prystowsky EN. Primary and secondary prevention of sudden cardiac death: the role of the implantable cardioverter defibrillator. 2(4):197–205.

Antibiotic therapy

Shah PK. Relationship between infection and coronary heart disease: results of two studies [ACC Update]. 2(4):209–210.

Aortic insufficiency

Lepor NE. Best of the 2001 ACC annual Snowmass Cardiovascular Conference [Meeting Review]. 2(4):206–208.

Aortic stenosis

Best of the AHA Scientific Sessions 2000 [Meeting Review]. 2(1):6–24, 60.

Aortic valve replacement

Lepor NE. Best of the 2001 ACC annual Snowmass Cardiovascular Conference [Meeting Review]. 2(4):206–208.

Aortobifemoral bypass surgery

Creager MA. Takayasu arteritis. 2(4):211–214.

Arteries

Izzo JL Jr, Shykoff BE. Arterial stiffness: clinical relevance, measurement, and treatment. 2(1):29–40.

Atheroablation

Stone GW, Tumlin JA, Madyoon H, et al. Design and rationale of CONTRAST_a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy. 2(suppl 1):S31–S36.

Atherosclerosis

- Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
- Best of the AHA Scientific Sessions 2000 [Meeting Review]. 2(1):6–24, 60.
- Chyu K-Y, Shah PK. The role of inflammation in plaque disruption and thrombosis. 2(2):82–91.
- Izzo JL Jr, Shykoff BE. Arterial stiffness: clinical relevance, measurement, and treatment. 2(1):29–40.
- Vogel RA. Update on inflammatory markers [Meeting Review]. 2(2):94–96.

ATLAS Trial

- Fonarow GC. Acute coronary events as a trigger of sudden death in heart failure. 2(2):105.

Atrial arrhythmias

- Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.

Atypical chest pain

- Dillon GA, Jacobs AK. Acute coronary syndrome in a young woman. 2(3):166:171.

Balloon angioplasty

- Garasic JM, Creager MA. Percutaneous interventions for lower-extremity peripheral atherosclerotic disease. 2(3):120–125.

Bare-metal stent

- Hiatt BL, Carter AJ, Yeung AC. The drug-eluting stent: is it the Holy Grail? 2(4):190–196.

β-blockers

- Best of the AHA Scientific Sessions 2000 [Meeting Review]. 2(1):6–24, 60.

Blood pressure

- Izzo JL Jr. Scrutinizing systolic blood pressure [Literature Review]. 2(2):111–113.
- Izzo JL Jr, Shykoff BE. Arterial stiffness: clinical relevance, measurement, and treatment. 2(1):29–40.

Brachytherapy

- Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
- Holmes DR Jr. In-stent restenosis. 2(3):115–119.

B-type natriuretic peptide

- Fonarow GC. BNP as treatment marker [Literature Review]. 2(3):174–176.
- Fonarow GC. Nesiritide: practical guide to its safe and effective use. 2(suppl 2):S32–S35.

Cardiac resynchronization therapy

- Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.

Cardiovascular disease

- Dillon GA, Jacobs AK. Acute coronary syndrome in a young woman. 2(3):166:171.

Carvedilol

- Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
- Lepor NE. Best of the 2001 ACC annual Snowmass Cardiovascular Conference [Meeting Review]. 2(4):206–208.

Catecholamines

- Lepor NE. Best of the 2001 ACC annual Snowmass Cardiovascular Conference [Meeting Review]. 2(4):206–208.

Chelation therapy

- Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.

Chemical myomectomy

- Kar S, Makkar R. Percutaneous transluminal septal myocardial ablation: a novel, nonsurgical treatment for symptomatic hypertrophic cardiomyopathy. 2(2):97–102.

Chlamydia pneumoniae

- Shah PK. Relationship between infection and coronary heart disease: results of two studies [ACC Update]. 2(4):209–210.

Cholesterol

- Best of the AHA Scientific Sessions 2000 [Meeting Review]. 2(1):6–24, 60.
- Lepor NE, Vogel RE. Summary of the third report of the National Cholesterol Education Program Adult Treatment Panel III. 2(3):160–165.
- Vogel RA. C-reactive protein as a predictor of coronary event risk [Literature Review]. 2(4):225.

Chronic renal insufficiency

- Kini A, Sharma SK. Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention. 2(suppl 1):S19–S25.

Clinical trials

- Shah PK. Relationship between infection and coronary heart disease: results of two studies [ACC Update].

2(4):209–210.

Congestive heart failure

- Best of the AHA Scientific Sessions 2000 [Meeting Review]. 2(1):6–24, 60.
- Fonarow GC. BNP as treatment marker [Literature Review]. 2(3):174–176.
- Lepor NE. Best of the 2001 ACC annual Snowmass Cardiovascular Conference [Meeting Review]. 2(4):206–208.
- Rayburn BK, Bourge RC. Nesiritide: a unique therapeutic cardiac peptide. 2(suppl 2):S25–S31.
- Young JB. New therapeutic choices in the management of acute congestive heart failure. 2(suppl 2):S19–S24.

Contrast

- Kini A, Sharma SK. Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention. 2(suppl 1):S19–S25.

Coronary angiography

- Passalaris J, Szulc M, Dubowsky J, Hachamovitch R. Acute myocardial infarction following recovery from a normal treadmill exercise test. 2(2):48–57, 60.

Coronary artery bypass

- Kar S, Shah PK. Acute coronary syndrome caused by coronary artery dissection mimicking acute plaque rupture. 2(4):215–219.

Coronary artery bypass graft surgery

- Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.

Coronary artery disease

- Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
- Best of the AHA Scientific Sessions 2000 [Meeting Review]. 2(1):6–24, 60.
- Chyu K-Y, Shah PK. The role of inflammation in plaque disruption and thrombosis. 2(2):82–91.
- Dillon GA, Jacobs AK. Acute coronary syndrome in a young woman. 2(3):166–171.
- Gersh BJ. Percutaneous transluminal coronary angioplasty and diabetes [Literature Review]. 2(4):220–223.
- Hachamovitch R. Risk assessment of patients with known or suspected CAD using stress myocardial perfu-

- sion SPECT. Part II: determining cost-effective test strategies. 2(1):41–47.
- Lepor NE. Managing diabetes and CAD [Literature Review]. 2(4):223–224.
- Coronary balloon angioplasty**
Stone GW, Tumlin JA, Madyoon H, et al. Design and rationale of CONTRAST—a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy. 2(suppl 1):S31–S36.
- Coronary disease**
Izzo JL Jr, Shykoff BE. Arterial stiffness: clinical relevance, measurement, and treatment. 2(1):29–40.
- Coronary disease prevention**
Lepor NE, Vogel RE. Summary of the third report of the National Cholesterol Education Program Adult Treatment Panel III. 2(3):160–165.
- Coronary heart disease**
Shah PK. Relationship between infection and coronary heart disease: results of two studies [ACC Update]. 2(4):209–210.
- C-reactive protein**
Vogel RA. C-reactive protein as a predictor of coronary event risk [Literature Review]. 2(4):224–225.
- Creatinine**
Bailey SR. Past and present attempts to prevent radiocontrast nephropathy. 2(suppl 1):S14–S18.
Madyoon H. Clinical experience with the use of fenoldopam for prevention of radiocontrast nephropathy in high-risk patients. 2(suppl 1):S26–S30.
- Critical limb ischemia**
Garasic JM, Creager MA. Percutaneous interventions for lower-extremity peripheral atherosclerotic disease. 2(3):120–125.
- CURE Trial**
Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
- DAPPAF Trial**
Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
- Diabetes**
Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
Gersh BJ. Percutaneous transluminal coronary angioplasty and diabetes [Literature Review]. 2(4):220–223.
Lepor NE. Managing diabetes and CAD [Literature Review]. 2(4):223–224.
- Dilated cardiomyopathy**
Fonarow GC. Dilated cardiomyopathy can result from mutations in sarcomere protein genes [Literature Review]. 2(2):103–104.
- Dopamine receptors**
Bailey SR. Past and present attempts to prevent radiocontrast nephropathy. 2(suppl 1):S14–S18.
- Dosing errors**
Martin Stone S, Neepa R, Nei J. Problems and pitfalls in cardiac drug therapy. 2(3):126–142.
- Drug-eluting stent**
Hiatt BL, Carter AJ, Yeung AC. The drug-eluting stent: is it the Holy Grail? 2(4):190–196.
- Drug interactions**
Martin Stone S, Neepa R, Nei J. Problems and pitfalls in cardiac drug therapy. 2(3):126–142.
- Dual-chamber pacing**
Kar S, Makkar R. Percutaneous transluminal septal myocardial ablation: a novel, nonsurgical treatment for symptomatic hypertrophic cardiomyopathy. 2(2):97–102.
- Dyslipidemia**
Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
- Electron beam computed tomography**
Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
Hachamovitch R. Incorporation of electron beam CT into routine testing algorithms: do we "just do it"? [Literature Review]. 2(2):110–111.
- Electronic resources**
Martin Stone S, Neepa R, Nei J. Problems and pitfalls in cardiac drug therapy. 2(3):126–142.
- Electrophysiology**
Packer DL. Congenital long QT syndrome [Literature Review]. 2(1):26–28.
- Endothelin receptor antagonist**
Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
Young JB. New therapeutic choices in the management of acute congestive heart failure. 2(suppl 2):S19–S24.
- Exercise test**
Hachamovitch R. Risk assessment of patients with known or suspected CAD using stress myocardial perfusion SPECT. Part II: determining cost-effective test strategies. 2(1):41–47.
- Fenoldopam**
Madyoon H. Clinical experience with the use of fenoldopam for prevention of radiocontrast nephropathy in high-risk patients. 2(suppl 1):S26–S30.
Mathur VS. Pathophysiology of radiocontrast nephropathy and use of fenoldopam for its prevention. 2(suppl 1):S4–S8.
Mehran R, Ashby DT. Radiocontrast-induced acute renal failure: allocations and outcomes. 2(suppl 1):S9–S13.
Stone GW, Tumlin JA, Madyoon H, et al. Design and rationale of CONTRAST—a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy. 2(suppl 1):S31–S36.
- Forced diuresis**
Bailey SR. Past and present attempts to prevent radiocontrast nephropathy. 2(suppl 1):S14–S18.
- Gene therapy**
Creager MA. Current issues in vascular disease [Meeting Review]. 2(2):92–93.
- GUSTO V Trial**
Results of the GUSTO V Trial [Literature Review]. 2(3):172–173.
- Heart failure**
Fonarow GC. Acute coronary events as a trigger of sudden death in heart failure. 2(2):105.
Fonarow GC. Dilated cardiomyopathy can result from mutations in sarcomere protein genes [Literature Review]. 2(2):103–104.
Fonarow GC. The treatment targets in acute decompensated heart failure. 2(suppl 2):S7–S12.
Fonarow GC. Nesiritide: practical guide to its safe and effective use. 2(suppl 2):S32–S35.
Fonarow GC. Vasopeptidase inhibition in patients with heart failure [Literature Review]. 2(2):104.
Fonarow GC, Young JB. Success with

- heart failure: new strategies to reverse acute decompensation. 2(suppl 2):S1.
- Shah M, Ali V, Lamba S, Abraham WT. Pathophysiology and clinical spectrum of acute congestive heart failure. 2(suppl 2):S2–S6.
- Hemodynamics**
- Fonarow GC. The treatment targets in acute decompensated heart failure. 2(suppl 2):S7–S12.
- Izzo JL Jr, Shykoff BE. Arterial stiffness: clinical relevance, measurement, and treatment. 2(1):29–40.
- Shah M, Ali V, Lamba S, Abraham WT. Pathophysiology and clinical spectrum of acute congestive heart failure. 2(suppl 2):S2–S6.
- Herbal treatments**
- Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
- Heterozygous familial hyperlipidemia**
- Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
- High-sensitivity C-reactive protein
- Vogel RA. Update on inflammatory markers [Meeting Review]. 2(2):94–96.
- Hypercholesterolemia**
- Lepor NE, Vogel RE. Summary of the third report of the National Cholesterol Education Program Adult Treatment Panel III. 2(3):160–165.
- Hypertension**
- Best of the AHA Scientific Sessions 2000 [Meeting Review]. 2(1):6–24, 60.
- Izzo JL Jr. Scrutinizing systolic blood pressure [Literature Review]. 2(2):111–113.
- Izzo JL Jr, Shykoff BE. Arterial stiffness: clinical relevance, measurement, and treatment. 2(1):29–40.
- Hydration**
- Bailey SR. Past and present attempts to prevent radiocontrast nephropathy. 2(suppl 1):S14–S18.
- Hypertrophic obstructive cardiomyopathy**
- Kar S, Makkar R. Percutaneous transluminal septal myocardial ablation: a novel, nonsurgical treatment for symptomatic hypertrophic cardiomyopathy. 2(2):97–102.
- Implantable cardioverter defibrillator**
- Prystowsky EN. Primary and secondary prevention of sudden cardiac death: the role of the implantable cardioverter defibrillator. 2(4):197–205.
- Swerdlow CD, Zhang X. Implantable cardioverter defibrillator shocks: a troubleshooting guide. 2(2):61–72.
- Inflammation**
- Chyu K-Y, Shah PK. The role of inflammation in plaque disruption and thrombosis. 2(2):82–91.
- Vogel RA. Update on inflammatory markers [Meeting Review]. 2(2):94–96.
- Inflammatory markers**
- Vogel RA. Update on inflammatory markers [Meeting Review]. 2(2):94–96.
- Inotrope**
- Maisel AS. B-type natriuretic peptide (BNP) levels: diagnosis and therapeutic potential. 2(suppl 2):S13–S18.
- In-stent restenosis**
- Best of the AHA Scientific Sessions 2000 [Meeting Review]. 2(1):6–24, 60.
- Intermittent claudication**
- Garasic JM, Creager MA. Percutaneous interventions for lower-extremity peripheral atherosclerotic disease. 2(3):120–125.
- Interventional cardiology**
- Results of the GUSTO V Trial [Literature Review]. 2(3):172–173.
- Intimal hyperplasia**
- Hiatt BL, Carter AJ, Yeung AC. The drug-eluting stent: is it the Holy Grail? 2(4):190–196.
- Intracoronary growth factor**
- Hachamovitch R. Intracoronary growth factor and myocardial perfusion [Literature Review]. 2(2):109–110.
- Ischemia, mesenteric**
- Creager MA. Current issues in vascular disease [Meeting Review]. 2(2):92–93.
- Left ventricular dysfunction**
- Lepor NE. Best of the 2001 ACC annual Snowmass Cardiovascular Conference [Meeting Review]. 2(4):206–208.
- Left ventricular pressure**
- Maisel AS. B-type natriuretic peptide (BNP) levels: diagnosis and therapeutic potential. 2(suppl 2):S13–S18.
- Lipid disorders**
- Vogel RA. Reducing risk of stroke and fracture [Literature Review]. 2(2):113–14.
- Lymphedema**
- Creager MA. Current issues in vascular disease [Meeting Review]. 2(2):92–93.
- Mapping systems**
- Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
- MASS II Trial**
- Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
- Matrix formation**
- Holmes DR Jr. In-stent restenosis. 2(3):115–119.
- Medication error**
- Martin Stone S, Neepa R, Nei J. Problems and pitfalls in cardiac drug therapy. 2(3):126–142.
- Metoprolol**
- Lepor NE. Best of the 2001 ACC annual Snowmass Cardiovascular Conference [Meeting Review]. 2(4):206–208.
- MIRACLE Trial**
- Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
- Mitral insufficiency**
- Lepor NE. Best of the 2001 ACC annual Snowmass Cardiovascular Conference [Meeting Review]. 2(4):206–208.
- Mitral regurgitation**
- Best of the AHA Scientific Sessions 2000 [Meeting Review]. 2(1):6–24, 60.
- Playford D, Weyman AE. Mitral valve prolapse: time for a fresh look. 2(2):73–81.
- Mitral valve prolapse**
- Playford D, Weyman AE. Mitral valve prolapse: time for a fresh look. 2(2):73–81.
- Mitral valve replacement**
- Lepor NE. Best of the 2001 ACC annual Snowmass Cardiovascular Conference [Meeting Review]. 2(4):206–208.
- Molecular cardiology**
- Hachamovitch R. Intracoronary growth factor and myocardial perfusion [Literature Review]. 2(2):109–110.
- Mortality**
- Fonarow GC. The treatment targets in acute decompensated heart failure. 2(suppl 2):S7–S12.
- Myocardial infarction**
- Best of the AHA Scientific Sessions

- 2000 [Meeting Review]. 2(1):6–24, 60.
- Gersh BJ. Myocardial infarction [Literature Review]. 2(3):174–176.
- Kar S, Shah PK. Acute coronary syndrome caused by coronary artery dissection mimicking acute plaque rupture. 2(4):215–219.
- Passalaris J, Szulc M, Dubowsky J, Hachamovitch R. Acute myocardial infarction following recovery from a normal treadmill exercise test. 2(1):48–57, 60.
- Myocardial perfusion imaging**
Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
- Natriuretic peptides**
Rayburn BK, Bourge RC. Nesiritide: a unique therapeutic cardiac peptide. 2(suppl 2):S25–S31.
- Shah M, Ali V, Lamba S, Abraham WT. Pathophysiology and clinical spectrum of acute congestive heart failure. 2(suppl 2):S2–S6.
- Young JB. New therapeutic choices in the management of acute congestive heart failure. 2(suppl 2):S19–S24.
- Neointimal hyperplasia**
Holmes DR Jr. In-stent restenosis. 2(3):115–119.
- Nesiritide**
Fonarow GC. Nesiritide: practical guide to its safe and effective use. 2(suppl 2):S32–S35.
- Fonarow GC, Young JB. Success with heart failure: new strategies to reverse acute decompensation. 2(suppl 2):S1.
- Rayburn BK, Bourge RC. Nesiritide: a unique therapeutic cardiac peptide. 2(suppl 2):S25–S31.
- Neurohormonal factors**
Maisel AS. B-type natriuretic peptide (BNP) levels: diagnosis and therapeutic potential. 2(suppl 2):S13–S18.
- Shah M, Ali V, Lamba S, Abraham WT. Pathophysiology and clinical spectrum of acute congestive heart failure. 2(suppl 2):S2–S6.
- Norepinephrine**
Shah M, Ali V, Lamba S, Abraham WT. Pathophysiology and clinical spectrum of acute congestive heart failure. 2(suppl 2):S2–S6.
- Nuclear cardiology**
Hachamovitch R. Incorporation of electron beam CT into routine testing algorithms: do we "just do it"? [Literature Review]. 2(2):110–111.
- NYHA**
Maisel AS. B-type natriuretic peptide (BNP) levels: diagnosis and therapeutic potential. 2(suppl 2):S13–S18.
- Pacing, biventricular**
Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
- Pacing, dual-site**
Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
- Percutaneous coronary intervention**
Kini A, Sharma SK. Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention. 2(suppl 1):S19–S25.
- Percutaneous interventional strategies**
Garasic JM, Creager MA. Percutaneous interventions for lower-extremity peripheral atherosclerotic disease. 2(3):120–125.
- Percutaneous transluminal angioplasty**
Creager MA. Takayasu arteritis. 2(4):211–214.
- Percutaneous transluminal coronary angioplasty**
Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
- Gersh BJ. Percutaneous transluminal coronary angioplasty and diabetes [Literature Review]. 2(4):220–223.
- Percutaneous transluminal septal myocardial ablation**
Kar S, Makkar R. Percutaneous transluminal septal myocardial ablation: a novel, nonsurgical treatment for symptomatic hypertrophic cardiomyopathy. 2(2):97–102.
- Peripheral arterial disease**
Garasic JM, Creager MA. Percutaneous interventions for lower-extremity peripheral atherosclerotic disease. 2(3):120–125.
- Positive inotropic response**
Young JB. New therapeutic choices in the management of acute congestive heart failure. 2(suppl 2):S19–S24.
- Positron emission tomography**
Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
- Premature ventricular complexes**
Prystowsky EN. Primary and secondary prevention of sudden cardiac death: the role of the implantable cardioverter defibrillator. 2(4):197–205.
- Preventative cardiology**
Vogel RA. Update on inflammatory markers [Meeting Review]. 2(2):94–96.
- Pulmonary capillary wedge pressure**
Fonarow GC. The treatment targets in acute decompensated heart failure. 2(suppl 2):S7–S12.
- Radiocontrast nephropathy**
Bailey SR. Past and present attempts to prevent radiocontrast nephropathy. 2(suppl 1):S14–S18.
- Kini A, Sharma SK. Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention. 2(suppl 1):S19–S25.
- Lepor NS. Radiocontrast nephropathy: managing the high-risk patient. 2(suppl 1):S1–S3.
- Madyoon H. Clinical experience with the use of fenoldopam for prevention of radiocontrast nephropathy in high-risk patients. 2(suppl 1):S26–S30.
- Mathur VS. Pathophysiology of radiocontrast nephropathy and use of fenoldopam for its prevention. 2(suppl 1):S4–S8.
- Mehran R, Ashby DT. Radiocontrast-induced acute renal failure: allocations and outcomes. 2(suppl 1):S9–S13.
- Stone GW, Tumlin JA, Madyoon H, et al. Design and rationale of CONTRAST—a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy. 2(suppl 1):S31–S36.
- Radionuclide imaging**
Hachamovitch R. Risk assessment of patients with known or suspected CAD using stress myocardial perfusion SPECT. Part II: determining cost-effective test strategies. 2(1):41–47.
- Reductase inhibitors**
Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
- Renal artery stenosis**
Creager MA. β -blockers for vascular

- surgery and angioplasty for renal artery stenosis [Literature Review]. 2(1):25–26.
- Renin-angiotensin-aldosterone system**
Shah M, Ali V, Lamba S, Abraham WT. Pathophysiology and clinical spectrum of acute congestive heart failure. 2(suppl 2):S2–S6.
- Restenosis**
Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
Hiatt BL, Carter AJ, Yeung AC. The drug-eluting stent: is it the Holy Grail? 2(4):190–196.
Holmes DR Jr. In-stent restenosis. 2(3):115–119.
- Revascularization**
Leopold JA, Jacobs AK. Catheter-based revascularization strategies for acute coronary syndromes in women. 2(4):181–189.
- Risk factors**
Dillon GA, Jacobs AK. Acute coronary syndrome in a young woman. 2(3):166:171.
Hachamovitch R. Risk assessment of patients with known or suspected CAD using stress myocardial perfusion SPECT. Part II: determining cost-effective test strategies. 2(1):41–47.
- Risk stratification**
Hachamovitch R. Risk assessment of patients with known or suspected CAD using stress myocardial perfusion SPECT. Part II: determining cost-effective test strategies. 2(1):41–47.
- Rosuvastatin**
Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
- Selective estrogen receptor modulators**
Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
- Shocks, inappropriate**
Swerdlow CD, Zhang X. Implantable cardioverter defibrillator shocks: a troubleshooting guide. 2(2):61–72.
- Single photon emission computed tomography**
Best of the ACC Scientific Session 2001 [Meeting Review]. 2(3):143–159.
- Sirolimus-coated stent**
Hiatt BL, Carter AJ, Yeung AC. The drug-eluting stent: is it the Holy Grail? 2(4):190–196.
- Stent implantation**
Stone GW, Tumlin JA, Madyoon H, et al. Design and rationale of CONTRAST—a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy. 2(suppl 1):S31–S36.
- Stents**
Faxon DP. Biodegradable stents: are they finally here? [Literature Review]. 2(2):106–107.
Faxon DP. Stenting plus abciximab vs tPA in acute myocardial infarction [Literature Review]. 2(2):107–108.
Holmes DR Jr. In-stent restenosis. 2(3):115–119.
Kar S, Shah PK. Acute coronary syndrome caused by coronary artery dissection mimicking acute plaque rupture. 2(4):215–219.
- Stress testing**
Passalaris J, Szulc M, Dubowsky J, Hachamovitch R. Acute myocardial infarction following recovery from a normal treadmill exercise test. 2(1):48–57, 60.
- Stroke**
Vogel RA. Reducing risk of stroke and fracture [Literature Review]. 2(2):113–14.
- ST-segment elevation**
Dillon GA, Jacobs AK. Acute coronary syndrome in a young woman. 2(3):166:171.
- Sudden cardiac death**
Prystowsky EN. Primary and secondary prevention of sudden cardiac death: the role of the implantable cardioverter defibrillator. 2(4):197–205.
- Surgical septal myotomy-myectomy**
Kar S, Makkar R. Percutaneous transluminal septal myocardial ablation: a novel, nonsurgical treatment for symptomatic hypertrophic cardiomyopathy. 2(2):97–102.
- Swan-Ganz**
Maisel AS. B-type natriuretic peptide (BNP) levels: diagnosis and therapeutic potential. 2(suppl 2):S13–S18.
- Takayasu arteritis**
Creager MA. Takayasu arteritis. 2(4):211–214.
- Thrombosis**
Chyu K-Y, Shah PK. The role of inflammation in plaque disruption and thrombosis. 2(2):82–91.
- Tissue plasminogen activator**
Stenting plus abciximab vs tPA in acute myocardial infarction [Literature Review]. 2(2):107–108.
- Triglycerides**
Lepor NE, Vogel RE. Summary of the third report of the National Cholesterol Education Program Adult Treatment Panel III. 2(3):160–165.
- Valvular heart disease**
Best of the AHA Scientific Sessions 2000 [Meeting Review]. 2(1):6–24, 60.
- Vascular resistance**
Izzo JL Jr, Shykoff BE. Arterial stiffness: clinical relevance, measurement, and treatment. 2(1):29–40.
- Vasodilators**
Lepor NE. Best of the 2001 ACC annual Snowmass Cardiovascular Conference [Meeting Review]. 2(4):206–208.
Maisel AS. B-type natriuretic peptide (BNP) levels: diagnosis and therapeutic potential. 2(suppl 2):S13–S18.
Rayburn BK, Bourge RC. Nesiritide: a unique therapeutic cardiac peptide. 2(suppl 2):S25–S31.
- Vasopeptidase inhibition**
Fonarow GC. Vasopeptidase inhibition in patients with heart failure [Literature Review]. 2(2):104.
- Ventricular fibrillation**
Prystowsky EN. Primary and secondary prevention of sudden cardiac death: the role of the implantable cardioverter defibrillator. 2(4):197–205.
- Ventricular tachycardia**
Prystowsky EN. Primary and secondary prevention of sudden cardiac death: the role of the implantable cardioverter defibrillator. 2(4):197–205.
Swerdlow CD, Zhang X. Implantable cardioverter defibrillator shocks: a troubleshooting guide. 2(2):61–72.
- Women**
Dillon GA, Jacobs AK. Acute coronary syndrome in a young woman. 2(3):166:171.
Leopold JA, Jacobs AK. Catheter-based revascularization strategies for acute coronary syndromes in women. 2(4):181–189.